Ann: FY17 Analyst Pack, page-52

Just on this - keep in mind the impairment is temprorary (see my post earlier) - just because the DTA generated from the US ops is not being recognised now - it can still be used if / when the us generates profits. It's just off balance sheet and there are typically no time restrictions

Anyway I thought the results were great particularly us growth - not really seeing a compelling argument in any of the posts above that the results were poor.

Nearmap is volatile and reasonably liquid for a small cap. The recent price action doesn't concern me too much. It's actually a great trading stock but I'm a long term holder on this one and am more than happy to continue to hold.